Zobrazeno 1 - 8
of 8
pro vyhledávání: '"S. K. Miroshnichenko"'
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 24, Iss 2, Pp 140-156 (2024)
INTRODUCTION. The development of malignant neoplasms is associated with changes in the expression of small non-coding RNAs (miRNAs). This emphasises the need for research into the development of miRNA-targeted inhibitors as a promising approach to ca
Externí odkaz:
https://doaj.org/article/6690babde4ae4d89b7cb5b8712c94f88
Autor:
Valentin V. Vlassov, Elena V. Bichenkova, Marina A. Zenkova, Bahareh Amirloo, S. K. Miroshnichenko, O. A. Patutina
Publikováno v:
Russian Journal of Bioorganic Chemistry. 45:803-812
Nowadays, application of miRNases—artificial ribonucleases aimed at degradation of noncoding RNAs, in particular, miRNAs—represents one of the novel experimental approaches to inhibit tumorigenesis. miRNases integrate in their structure an addres
Autor:
Valentin V. Vlassov, Marina A. Zenkova, O. A. Patutina, M. A. Bazhenov, Dmitrii V. Pyshnyi, N. L. Mironova, S. K. Miroshnichenko
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-15 (2018)
Scientific Reports
Scientific Reports
Taking into account the important role of miRNA in carcinogenesis, oncogenic miRNAs are attractive molecules for gene-targeted therapy. Here, we developed a novel series of peptide-oligonucleotide conjugates exhibiting ribonuclease activity targeted
Publikováno v:
Russian Journal of Bioorganic Chemistry. 43:29-37
In the pathogenesis of malignancies, an active regulatory role belongs to small noncoding RNAs, miRNA (miR). miRNA expression profiles are often associated with the prognosis and therapeutic outcome of different oncological diseases. It is well known
Autor:
N. L. Mironova, Marina A. Zenkova, S. K. Miroshnichenko, Elena V. Bichenkova, Aleksandra V Sen'kova, O. A. Patutina, David Clarke, Valentin V. Vlassov
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Patutina, O A, Miroshnichenko, S K, Mironova, N L, Sen'kova, A V, Bichenkova, E, Clarke, D, Vlassov, V V & Zenkova, M 2019, ' Catalytic Knockdown of miR-21 by Artificial Ribonuclease: Biological Performance in Tumor Model ', Frontiers in Pharmacology . https://doi.org/10.3389/fphar.2019.00879
Frontiers in Pharmacology
Patutina, O A, Miroshnichenko, S K, Mironova, N L, Sen'kova, A V, Bichenkova, E, Clarke, D, Vlassov, V V & Zenkova, M 2019, ' Catalytic Knockdown of miR-21 by Artificial Ribonuclease: Biological Performance in Tumor Model ', Frontiers in Pharmacology . https://doi.org/10.3389/fphar.2019.00879
Frontiers in Pharmacology
Control of the expression of oncogenic small non-coding RNAs, notably microRNAs (miRNAs), is an attractive therapeutic approach. We report a design platform for catalytic knockdown of miRNA targets with artificial, sequence-specific ribonucleases. mi
Autor:
S. K. Miroshnichenko, O. A. Patutina
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in Pharmacology
Frontiers in Pharmacology
The search for effective strategies to inhibit tumorigenesis remains one of the most relevant scientific challenges. Among the most promising approaches is the direct modulation of the function of short non-coding RNAs, particularly miRNAs. These mol
Autor:
Valentin V. Vlassov, Marina A. Zenkova, O. A. Patutina, Dmitry A. Stetsenko, E. A. Burakova, Boris P. Chelobanov, Sidney Altman, A. A. Fokina, S. K. Miroshnichenko
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Forty years of research have shown that antisense oligonucleotides have great potential to target mRNAs of disease-associated genes and noncoding RNAs. Among the vast number of oligonucleotide backbone modifications, phosphorothioate mod
Autor:
Linda T. Trivoluzzi, S. K. Miroshnichenko, Marina A. Zenkova, Kepa K. Burusco, Elena V. Bichenkova, N. L. Mironova, O. A. Patutina, Richard A. Bryce, Valentin V. Vlassov
Publikováno v:
Patutina, O A, Bichenkova, E, Miroshnichenko, S K, Mironova, N L, Trivoluzzi, L, Burusco-Goni, K, Bryce, R, Vlassov, V V & Zenkova, M A 2017, ' miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells ', Biomaterials, vol. 122, pp. 163-178 . https://doi.org/10.1016/j.biomaterials.2017.01.018
MicroRNAs (miRNAs) are active regulators in malignant growth and constitute potential targets for anticancer therapy. Consequently, considerable effort has focused on identifying effective ways to modulate aberrant miRNA expression. Here we introduce